LONDON and PHILADELPHIA, March 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline announced today that it has re-submitted the supplemental New Drug Application (sNDA) for Avodart(R) (dutasteride) for prostate cancer risk reduction among men at increased risk of developing the disease to the US Food and Drug Administration (FDA).
The provision of this update to the European Regulatory authorities is also underway.
For more information about Avodart, please see the full prescribing information at www.gsk.com.
GlaxoSmithKline - one of the world’s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
CONTACT: GlaxoSmithKline Enquiries: UK Media enquiries: Philip Thomson,
(020) 8047 5502, or Claire Brough, (020) 8047 5502, Stephen Rea, (020) 8047
5502, Alexandra Harrison, (020) 8047 5502, Jo Revill, (020) 8047 5502; or
US Media enquiries: Nancy Pekarek, +1-919-483-2839, Mary Anne Rhyne,
+1-919-483-2839, Kevin Colgan, +1-919-483-2839, Sarah Alspach,
+1-919-483-2839; or European Analyst/Investor enquiries: David Mawdsley,
(020) 8047 5564, or Sally Ferguson, (020) 8047 5543, or Gary Davies, (020)
8047 5503; or US Analyst/ Investor enquiries: Tom Curry, +1-215-751-5419,
Jen Hill Baxter, +1-215-751-7002
Web site: http://www.gsk.com/
